MTMonica Tang

Monica Tang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Monica Tang has a total of 150 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Clinical and Biological Features of a Thickened Basement Membrane Zone in Asthma

    by Clarus Leung, Monica Tang, Walter E. Finkbeiner, Mats W. Johansson, Loren C. Denlinger, Nizar N. Jarjour, Mario Castro, Kaharu Sumino, Serpil C. Erzurum, Suzy A. Comhair, et al.

    Rationale: A subset of patients with asthma have airway pathology characterized by a thickened subepithelial basement membrane zone (“BMZ-thick asthma”). Objectives: To characterize the clinical features of BMZ-thick asthma and to determine if BMZ thickness accompanies specific patterns of inflammation in the airway epithelium. Methods: Design-based stereology was used to quantify BMZ thickness in endobronchial biopsy tissue sections from 109 patients with asthma and 41 healthy control subjects from SARP (Severe Asthma Research Program)–3, whose participants had undergone spirometry and gene expression profiling in airway epithelial brushings. Measurements and Main Results: The upper 90th-percentile value for BMZ thickness in the healthy cohort was 2.9 μM, and 35% of the asthma cohort had values above this upper limit. Compared with patients with BMZ-thin asthma, patients with BMZ-thick asthma were younger and had higher blood eosinophil numbers and serum immunoglobulin E concentrations that were specific to animal proteins. Mean prebronchodilator FEV1 was significantly lower in patients with BMZ-thick asthma than in those with BMZ-thin asthma, but postbronchodilator FEV1 was not. Upregulation of genes signifying IL-13 activation and the presence of mast cells were evident in epithelial brushings in patients with BMZ-thick asthma, but gene signatures for activation by IFN-γ or IL-17 were not. Conclusions: A thickened BMZ marks a subset of younger patients with asthma characterized by higher immunoglobulin E concentrations to animal aeroallergens and by increased bronchomotor tone occurring in the context of airway epithelial cells activated by IL-13 and infiltrated by mast cells.


  • Top Cited Papers

    Type 1 Immune Responses Related to Viral Infection Influence Corticosteroid Response in Asthma

    by John V. Fahy, Nathan D. Jackson, Satria P. Sajuthi, Elmar Pruesse, Camille M. Moore, Jamie L. Everman, Cydney Rios, Monica Tang, Marc Gauthier, Sally E. Wenzel, et al.

    Rationale: Corticosteroid-responsive type 2 (T2) inflammation underlies the T2-high asthma endotype. However, we hypothesized that type 1 (T1) inflammation, possibly related to viral infection, may also influence corticosteroid response. Objectives: To determine the frequency and within-patient variability of T1-high, T2-high, and T1/T2-high asthma endotypes and whether virally influenced T1-high disease influences corticosteroid response in asthma. Methods: Patients in SARP-3 (Severe Asthma Research Program-3) had sputum collected at baseline, after intramuscular (triamcinolone acetonide) corticosteroid treatment, and at 1- and 3-year follow-ups. Sputum cell RNA was used for whole-transcriptome gene network and viral metagenomic analyses. We then profiled patients as highly expressing T1 and/or T2 gene networks and established the influence of these endotypes on corticosteroid responsiveness and the likelihood of viral transcript detection in the airways. Measurements and Main Results: We found that 22% and 35% of patients with asthma highly expressed T1 and T2 network genes, respectively, and that 8.5% highly expressed both networks. Asthma severity outcomes were worse in T2-high compared with T1-high asthma and most severe in the T1-high/T2-high subgroup. Corticosteroid treatment strongly suppressed T2 but poorly suppressed T1 gene expression, and corticosteroid-associated improvements in FEV1 occurred only in patients with T1-low/T2-high disease and not in patients with T1-high/T2-high disease. Viral metagenomic analyses uncovered that 24% of asthma sputum samples tested positive for a respiratory virus, and high viral carriage was associated with 14-fold increased risk of T1-high disease. Conclusions: Airway T1 immune responses are relatively common in asthma, are largely corticosteroid resistant, and are associated with subclinical viral infection.


  • Open Access

    Peroxidase-mediated mucin cross-linking drives pathologic mucus gel formation in IL-13–stimulated airway epithelial cells

    by Maude A. Liegeois, Margaret Braunreuther, Annabelle R. Charbit, Wilfred W. Raymond, Monica Tang, Prescott G. Woodruff, Stephanie A. Christenson, Mario Castro, Serpil C. Erzurum, Elliot Israel, et al.

    Mucus plugs occlude airways to obstruct airflow in asthma. Studies in patients and in mouse models show that mucus plugs occur in the context of type 2 inflammation, and studies in human airway epithelial cells (HAECs) show that IL-13–activated cells generate pathologic mucus independently of immune cells. To determine how HAECs autonomously generate pathologic mucus, we used a magnetic microwire rheometer to characterize the viscoelastic properties of mucus secreted under varying conditions. We found that normal HAEC mucus exhibited viscoelastic liquid behavior and that mucus secreted by IL-13–activated HAECs exhibited solid-like behavior caused by mucin cross-linking. In addition, IL-13–activated HAECs shows increased peroxidase activity in apical secretions, and an overlaid thiolated polymer (thiomer) solution shows an increase in solid behavior that was prevented by peroxidase inhibition. Furthermore, gene expression for thyroid peroxidase (TPO), but not lactoperoxidase (LPO), was increased in IL-13–activated HAECs and both TPO and LPO catalyze the formation of oxidant acids that cross-link thiomer solutions. Finally, gene expression for TPO in airway epithelial brushings was increased in patients with asthma with high airway mucus plug scores. Together, our results show that IL-13–activated HAECs autonomously generated pathologic mucus via peroxidase-mediated cross-linking of mucin polymers.


  • A novel DNase assay reveals low DNase activity in severe asthma

    by Annabelle R. Charbit, Maude A. Liegeois, Wilfred W. Raymond, Suzy A. A. Comhair, Mats W. Johansson, Annette T. Hastie, Eugene R. Bleecker, Merritt Fajt, Mario Castro, Kaharu Sumino, et al.

    We developed a new DNase assay and used it to show that DNase activity is impaired in asthma airways.


  • A Novel Air Trapping Segment Score Identifies Opposing Effects of Obesity and Eosinophilia on Air Trapping in Asthma

    by Clarus Leung, Monica Tang, Brendan K. Huang, Sean B. Fain, Eric A. Hoffman, Jiwoong Choi, Eleanor M. Dunican, David T. Mauger, Loren C. Denlinger, Nizar N. Jarjour, et al.

    Rationale: Density thresholds in computed tomography (CT) lung scans quantify air trapping (AT) at the whole-lung level but are not informative for AT in specific bronchopulmonary segments. Objectives: To apply a segment-based measure of AT in asthma to investigate the clinical determinants of AT in asthma. Methods: In each of 19 bronchopulmonary segments in CT lung scans from 199 patients with asthma, AT was categorized as present if lung attenuation was less than −856 Hounsfield units at expiration in ≥15% of the lung area. The resulting AT segment score (0–19) was related to patient outcomes. Measurements and Main Results: AT varied at the lung segment level and tended to persist at the patient and lung segment levels over 3 years. Patients with widespread AT (≥10 segments) had more severe asthma (P < 0.05). The mean (±SD) AT segment score in patients with a body mass index ≥30 kg/m2 was lower than in patients with a body mass index <30 kg/m2 (3.5 ± 4.6 vs. 5.5 ± 6.3; P = 0.008), and the frequency of AT in lower lobe segments in obese patients was less than in upper and middle lobe segments (35% vs. 46%; P = 0.001). The AT segment score in patients with sputum eosinophils ≥2% was higher than in patients without sputum eosinophilia (7.0 ± 6.1 vs. 3.3 ± 4.9; P < 0.0001). Lung segments with AT more frequently had airway mucus plugging than lung segments without AT (48% vs. 18%; P ≤ 0.0001). Conclusions: In patients with asthma, air trapping is more severe in those with airway eosinophilia and mucus plugging, whereas those who are obese have less severe trapping because their lower lobe segments are spared.


  • Open Access

    A common polymorphism in the Intelectin-1 gene influences mucus plugging in severe asthma

    by Jamie L. Everman, Satria P. Sajuthi, Maude A. Liegeois, Nathan D. Jackson, Erik H. Collet, Michael C. Peters, Maurizio Chioccioli, Camille M. Moore, Bhavika B. Patel, Nathan Dyjack, et al.

    By incompletely understood mechanisms, type 2 (T2) inflammation present in the airways of severe asthmatics drives the formation of pathologic mucus which leads to airway mucus plugging. Here we investigate the molecular role and clinical significance of intelectin-1 (ITLN-1) in the development of pathologic airway mucus in asthma. Through analyses of human airway epithelial cells we find that ITLN1 gene expression is highly induced by interleukin-13 (IL-13) in a subset of metaplastic MUC5AC+ mucus secretory cells, and that ITLN-1 protein is a secreted component of IL-13-induced mucus. Additionally, we find ITLN-1 protein binds the C-terminus of the MUC5AC mucin and that its deletion in airway epithelial cells partially reverses IL-13-induced mucostasis. Through analysis of nasal airway epithelial brushings, we find that ITLN1 is highly expressed in T2-high asthmatics, when compared to T2-low children. Furthermore, we demonstrate that both ITLN-1 gene expression and protein levels are significantly reduced by a common genetic variant that is associated with protection from the formation of mucus plugs in T2-high asthma. This work identifies an important biomarker and targetable pathways for the treatment of mucus obstruction in asthma.


  • Top Cited Papers
    Open Access

    Utility of eosinophil peroxidase as a biomarker of eosinophilic inflammation in asthma

    by Monica Tang, Annabelle R. Charbit, Mats W. Johansson, Nizar N. Jarjour, Loren C. Denlinger, Wilfred W. Raymond, Michael C. Peters, Eleanor M. Dunican, Mario Castro, Kaharu Sumino, et al.


  • Open Access

    Persistent mucus plugs in proximal airways are consequential for airflow limitation in asthma

    by Brendan K. Huang, Brett M. Elicker, Travis S. Henry, Kimberly G. Kallianos, Lewis D. Hahn, Monica Tang, Franklin Heng, Charles E. McCulloch, Nirav R. Bhakta, Sharmila Majumdar, et al.

    BACKGROUND: Information about the size, airway location, and longitudinal behavior of mucus plugs in asthma is needed to understand their role in mechanisms of airflow obstruction and to rationally design muco-active treatments. METHODS: CT lung scans from 57 patients with asthma were analyzed to quantify mucus plug size and airway location, and paired CT scans obtained 3 years apart were analyzed to determine plug behavior over time. Radiologist annotations of mucus plugs were incorporated in an image-processing pipeline to generate size and location information that was related to measures of airflow. RESULTS: The length distribution of 778 annotated mucus plugs was multimodal, and a 12 mm length defined short (“stubby”, ≤12 mm) and long (“stringy”, >12 mm) plug phenotypes. High mucus plug burden was disproportionately attributable to stringy mucus plugs. Mucus plugs localized predominantly to airway generations 6–9, and 47% of plugs in baseline scans persisted in the same airway for 3 years and fluctuated in length and volume. Mucus plugs in larger proximal generations had greater effects on spirometry measures than plugs in smaller distal generations, and a model of airflow that estimates the increased airway resistance attributable to plugs predicted a greater effect for proximal generations and more numerous mucus plugs. CONCLUSION: Persistent mucus plugs in proximal airway generations occur in asthma and demonstrate a stochastic process of formation and resolution over time. Proximal airway mucus plugs are consequential for airflow and are in locations amenable to treatment by inhaled muco-active drugs or bronchoscopy. TRIAL REGISTRATION: Clinicaltrials.gov; NCT01718197, NCT01606826, NCT01750411, NCT01761058, NCT01761630, NCT01716494, and NCT01760915. FUNDING: AstraZeneca, Boehringer-Ingelheim, Genentech, GlaxoSmithKline, Sanofi–Genzyme–Regeneron, and TEVA provided financial support for study activities at the Coordinating and Clinical Centers beyond the third year of patient follow-up. These companies had no role in study design or data analysis, and the only restriction on the funds was that they be used to support the SARP initiative.


  • Open Access

    Prescribing practices of inhaled corticosteroids for premature infants in the neonatal intensive care unit

    by Monica Tang, Anna Ibrahim, Christopher Laughon, Kaila Moore, Angibel Tejada, Dean Tran, Ryan Kilpatrick, Rachel G. Greenberg, Christoph P. Hornik, Kanecia Zimmerman, et al.

    Objective: Despite limited safety and efficacy data, inhaled corticosteroids (ICS) are prescribed to premature infants in the neonatal intensive care unit (NICU). We examined contemporary use and risk factors for ICS use in the NICU. Study design: Infants <33 weeks gestational age and <1500 gm birth weight discharged from Pediatrix Medical Group NICUs between 2010 and 2020 were included. We evaluated the association between ICS prescription and clinical characteristics using univariable and multivariable logistic regression. Results: Of 74,123 infants from 308 NICUs, 9253 (12.5%) were prescribed ICS: budesonide, fluticasone, or beclomethasone. Diagnosis of bronchopulmonary dysplasia (BPD), earlier gestational age, male sex, longer mechanical ventilation, oxygen support, and systemic steroids were independent risk factors for ICS prescription. Conclusions: Use of ICS is common in many NICUs and is associated with a diagnosis of BPD and healthcare utilization. Prospective trials are needed to establish the safety, efficacy, and optimal indication in this vulnerable population.


  • Open Access

    Reply to Ikeda and Tomita

    by Monica Tang, David T. Mauger, John V. Fahy, Eleanor M. Dunican